Other substances

Plerixafor

A chemokine receptor antagonist.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Plerixafor is a CXCR4 receptor antagonist. It is used to mobilize hematopoietic stem and progenitor cells from bone marrow to blood for hematopoietic cell transplantation (LiverTox).

Plerixafor on DrugBank
Plerixafor on PubChem
Plerixafor on Wikipedia

Marketed as

MOZOBIL

 

Structure image - Plerixafor

C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3

Supporting references

Link Tested on Impact factor Notes Publication date
In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
Spike protein ACE2 Small molecule In silico 		in silico

Predicted to destabilize the SARS-CoV-2 Spike-host's ACE2 receptor interface.

 Dec/28/2020
Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
Small molecule In vitro 		in vitro bacteria-based assay 3.82

Displayed inhibitory activity against the potential ion channel ORF3a of SARS-CoV-2 in a bacterial model assay.

 Mar/23/2021

AI-suggested references

Link Publication date
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Mar/28/2022
Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach
Jul/07/2020
Export (.csv)